BUSINESS
Gilead says Remdesivir to cost US$2,340 for 5-day treatment - BNN Bloomberg
BUSINESS

Gilead says Remdesivir to cost US$2,340 for 5-day treatment - BNN Bloomberg

Published: June 29, 2020  |  3 min read, 694 words
WRITTEN BY
Your review will affect the following:
Continuous Play:The information you requested is not available at this time, please check back again soon.A person enters a building at Gilead Sciences Inc. headquarters in Foster City, California, U.S., on Thursday, March 19, 2020. Gilead Sciences stock jumped as much as 7% on Thursday, reaching a two-year high, as a Piper Sandler analyst doubled down on his call on the approval prospects for the biotech company's experimental therapy for the pandemic now sweeping the U.S. Photographer: David Paul Morris/Bloomberg, BloombergThe stock symbol {{StockChart.Ric}} does not existGilead Sciences... READ MORE
CRITIC
N/A
N/Ano rating
Critic Reviews: N/A
We calculate ratings after a minimum of three reviews.
USER
N/A
N/Ano rating
User Reviews: N/A
We calculate ratings after a minimum of three reviews.
TOP REVIEWS
There are no reviews yet.

CRITIC REVIEWS

There don't seem to be any reviews yet.

PUBLIC REVIEWS

There don't seem to be any reviews yet.